The market has been high on Crispr Therapeutics AG (CRSP) stock recently. CRSP gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.
Crispr Therapeutics AG has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRSP!
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With CRSP Stock Today?
Crispr Therapeutics AG (CRSP) stock is trading at $76.33 as of 3:43 PM on Tuesday, Aug 9, a decline of -$5.06, or -6.22% from the previous closing price of $81.39. The stock has traded between $74.57 and $78.57 so far today. Volume today is low. So far 1,198,766 shares have traded compared to average volume of 1,766,306 shares.
To see InvestorsObserver's Sentiment Score for Crispr Therapeutics AG click here.
More About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Click Here to get the full Stock Report for Crispr Therapeutics AG stock.